Work Area: Valuation

Latest content

The Roivant Sciences dealmaking strategy revolutionising life sciences IP monetisation

A deep dive into the trail-blazing biopharma business established by former hedge fund partner Vivek Ramaswamy

02 February 2021

A big buyer two years ago, Chinese company on entity list moves portfolio off its books

O-Film, a smartphone supplier that has counted Apple among its clients, spins 900+ assets to a related party as its business comes under pressure

26 January 2021

Chinese lidar manufacturer paid $20 million upfront plus ongoing royalties to settle Velodyne dispute

Hesai Photonics Technology reveals monetary details of settlement, which also involves ongoing royalty payments through 2030

22 January 2021

Six life sciences IP dealmaking trends to watch out for in 2021

Despite a turbulent 2020 for pharma transactions, it is possible to discern a few patterns for activity in the market this year

19 January 2021

Subsidies still matter in China’s patent world, but focus is shifting overseas

USPTO report on non-market patent incentives shows how Chinese applicants are being encouraged to obtain more foreign rights

14 January 2021

The keys to effective IP monetisation

Patent licensing is as much an art as it is a science, explain some of those featured in the new IAM Strategy 300 Global Leaders guide

22 December 2020

Three life sciences trade secrets and data strategy lessons

As non-patent assets become increasingly important, pharma and biotech innovators must adapt their IP strategies.

22 December 2020

Five key insights into 2020’s drug royalty transactions

It has been a year of creative and flexible deal-making with many life sciences entities taking advantage of the revenues this kind of IP monetisation can deliver

16 December 2020

It’s time for investors to re-assess intangibles

A recent report suggests Wall Street is beginning to realise that the rise of intangible assets has thrown a spanner into time-tested valuation models

12 December 2020

New patent politics put US public-private partnerships under threat, says BIO’s IP chief

In an exclusive interview, Hans Sauer talks of concerns over a shift in federal strategy and argues that government research funding should not be seen as a commercial investment

03 December 2020

Unlock unlimited access to all IAM content